In vitro PET/MRI diagnosis and targeted chemotherapy for cancer using radiolabeled nanoprobe : A theragnostic approach by Cho, Bo-Bae et al.
University of Wollongong 
Research Online 
Australian Institute for Innovative Materials - 
Papers Australian Institute for Innovative Materials 
1-1-2016 
In vitro PET/MRI diagnosis and targeted chemotherapy for cancer using 







Sang Y. Hwang 
Dongguk University, samhwang@uow.edu.au 
Jung Lee 
Dongguk University 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/aiimpapers 
 Part of the Engineering Commons, and the Physical Sciences and Mathematics Commons 
Recommended Citation 
Cho, Bo-Bae; Moon, Mi; Chellan, Justin; Hwang, Sang Y.; Lee, Jung; Jung, Soon Jae; Kim, Byung Chul; and 
Yu, Kook Hyun, "In vitro PET/MRI diagnosis and targeted chemotherapy for cancer using radiolabeled 
nanoprobe : A theragnostic approach" (2016). Australian Institute for Innovative Materials - Papers. 2677. 
https://ro.uow.edu.au/aiimpapers/2677 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
In vitro PET/MRI diagnosis and targeted chemotherapy for cancer using 
radiolabeled nanoprobe : A theragnostic approach 
Abstract 
The 68 Ga-labeled iron oxide (Fe 3 O 4 ) nanocomposites ( 68 Ga(NF)HFCNP) have been fabricated for 
positron emission tomography (PET)/magnetic resonance imaging (MRI) diagnosis and targeted cancer 
therapy. These radioisotopes labeled nanocomposites with folate conjugation have improved the 
targeting property toward cancer cells. The chemotherapeutic drug doxorubicin (DOX) was loaded with 68 
Ga-labeled Fe 3 O 4 nanoparticles ( 68 Ga(NF)HFCNP) via intermediate DOX-Fe 2+ complex. The average 
loading efficiency of DOX was 35% for NFHFCNP and 41% for HFCNP, respectively. In drug release profile, 
the release rate of DOX from the nanocomposite was increased with respect to time. The cell lines, KB 
and A549 treated with 68 Ga(NF)HFCNP showed high cell viability and excellent cell uptake. Meanwhile, 
the DOX-loaded nanocomposites exhibit high cytotoxicity toward these cell lines. These properties make 
68 Ga(NF)HFCNP nanocomposite as a potential dual theragnostic probe for PET/MRI and targeted 
chemotherapy for cancer cells. 
Disciplines 
Engineering | Physical Sciences and Mathematics 
Publication Details 
Cho, B., Moon, M. Mi., Chellan, J. Raj., Hwang, S. Hyuck., Lee, J. Hoon., Jung, S. Jae., Kim, B. Chul. & Yu, K. 
Hyun. (2016). In vitro PET/MRI diagnosis and targeted chemotherapy for cancer using radiolabeled 
nanoprobe : A theragnostic approach. Bulletin of the Korean Chemical Society, 37 (6), 886-892. 
Authors 
Bo-Bae Cho, Mi Moon, Justin Chellan, Sang Y. Hwang, Jung Lee, Soon Jae Jung, Byung Chul Kim, and 
Kook Hyun Yu 
This journal article is available at Research Online: https://ro.uow.edu.au/aiimpapers/2677 
In Vitro PET/MRI Diagnosis and Targeted Chemotherapy for Cancer
Using Radiolabeled Nanoprobe : A Theragnostic Approach
Bo-Bae Cho,† Mi Mi Moon,† Justin Raj Chellan,† Sang Hyuck Hwang,† Jung Hoon Lee,†
Soon Jae Jung,† Byung Chul Kim,† and Kook Hyun Yu†,‡,*
†Department of Chemistry, Dongguk University-Seoul, Seoul 100-715, Republic of Korea.
*E-mail: yukook@dongguk.edu,
‡Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea
Received February 5, 2016, Accepted March 24, 2016, Published online May 23, 2016
The 68Ga-labeled iron oxide (Fe3O4) nanocomposites (
68Ga(NF)HFCNP) have been fabricated for posi-
tron emission tomography (PET)/magnetic resonance imaging (MRI) diagnosis and targeted cancer ther-
apy. These radioisotopes labeled nanocomposites with folate conjugation have improved the targeting
property toward cancer cells. The chemotherapeutic drug doxorubicin (DOX) was loaded with 68Ga-
labeled Fe3O4 nanoparticles (
68Ga(NF)HFCNP) via intermediate DOX–Fe2+ complex. The average load-
ing efficiency of DOX was 35% for NFHFCNP and 41% for HFCNP, respectively. In drug release profile,
the release rate of DOX from the nanocomposite was increased with respect to time. The cell lines, KB
and A549 treated with 68Ga(NF)HFCNP showed high cell viability and excellent cell uptake. Meanwhile,
the DOX-loaded nanocomposites exhibit high cytotoxicity toward these cell lines. These properties make
68Ga(NF)HFCNP nanocomposite as a potential dual theragnostic probe for PET/MRI and targeted chemo-
therapy for cancer cells.
Keywords: Gallium-68, Doxorubicin, Chemotherapy, Positron emission tomography,
Magnetic resonance imaging
Introduction
Cancer is a disease which can break orderly process of nor-
mal cells in the body and causes death. Despite the techni-
cal advancement of cancer diagnosis and therapy for last
few decades, it has remained as a major public health con-
cern. There are conventional treatments for cancer such as
surgery, radiation, hormone, and chemotherapy. Among
these, the most common therapeutic approach is chemother-
apy which has been used either alone or in combination
with other therapeutic techniques.1–3 Chemotherapy uses a
highly efficient antineoplastic agent that kills cancer cells
by preventing cell division or by drug toxicity which
includes the anthracycline antibiotics; adriamycin and dox-
orubicin (DOX). DOX has been proven to be a very effec-
tive drug for the treatment of various cancers.4
Nevertheless, the severe side effects such as drug resistance
and non-selective cytotoxicity curtail the utility of this drug.
Therefore, it is necessary to develop site-specific delivery
system to transfer drug and it can nullify the major obsta-
cles of toxicity and drug resistance.2–4 Generally, nano-
scale anticancer drug carriers have favorable properties like
enhanced permeability and retention (EPR) effect. The
highly stable nano-based carrier avoids the rapid renal
excretion and prevents recognition by the reticuloendothe-
lial system (RES), which enable effective accumulation in a
solid tumor. As a result, those properties can decrease
severe side effects of the drug by minimizing non-specific
interactions.3,5,6 Recently, anticancer drug carriers based on
magnetic nanoparticles (NPs) are effective and attractive
approach for the biomedical applications. Superparamag-
netic iron oxide (Fe3O4) NPs are benefited as probe and
delivery system for biological diagnosis and therapy
because of their excellent chemical stability and
biocompatibility.7–11 Specifically, radioisotope-labeled mag-
netic NPs are ideal probe for positron emission tomography
(PET)/magnetic resonance imaging (MRI) which is a power-
ful tool to obtain necessary information in biomedicine.7,8,12
In the beginning, 11C (t1/2 = 20 min),
13N (t1/2 = 10 min),
15O (t1/2 = 2 min), and
18F (t1/2 = 110 min) were the most
used organic radionuclides for PET analysis. However, they
have some limitations including high production cost for
using cyclotron and relatively short half-lives. One of the
alternative approach is to use metal radionuclide including
68Ga (t1/2 = 68 min, β+ = 89% and electron capture (EC) =
11%), which can be obtained easily from 68Ge/68Ga gener-
ator without the serve of cyclotron.8,13,14 Previously, we
have reported the 68Ga-labeled water dispersible Fe3O4 NPs
via ρ-SCN-Bn-1,4,7-triazacyclononane-1,4,7-triacetic acid
(NOTA) as chelate agent for dual modality of PET and
MRI diagnosis. Herein, we evaluated the 68Ga-labeled and
folate-conjugated Fe3O4 NPs for in vitro PET/MRI diagno-
sis with enhanced targeted therapy. Folate can be applied as
a targeting agent for chemotherapy because of their high
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binding affinity toward the cancer cells. Many studies have
been reported on folate-conjugated nano-scale drug carriers
using NPs,15,16, polymeric micelles,17,18 and liposomes19 for
tumor targeting. Furthermore, the fabricated radioisotope-
labeled nanocomposites were conjugated with anticancer
drug DOX. The loading efficiency and release profile of the
drug and its anticancer potential were studied in detail.
Experimental
2-(p-Isothiocyanatobenzyl)-1,4,7-triazacyclononane-N,
N0N00-triacetic acid trihydrochloride (p-SCN-Bn-NOTA)
was purchased from Futurechem (Seoul, Korea). The GaCl3
salt (mixture of two isotopes [69Ga-61.2% and 71Ga-38.8%])
and other chemical reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA) and were used without further
purification. Roswell Park Memorial Institute (RPMI) 1640
medium, Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum, penicillin–streptomycin and phosphate-
buffered saline (PBS, pH 7.4) were obtained from Gibco,
Life Science, Life Technologies (Seoul, Korea). A murine
colon cancer cell line CT-26 (folate receptor positive; FR+),
human breast cancer cell line SK-BR-3 (folate receptor nega-
tive; FR–), HeLa contaminated cell line KB (FR+) and lung
cancer cell line A 549 (FR–) were purchased from Korea Cell
Line Bank. (Seoul, Korea) 20–22.
Preparation of HFCNP and NFHFCNP. 68Ga-labeled
NPs were synthesized according to the scheme shown in
Figure S1, Supporting Information. In the first step, the cit-
rate was attached on the surface of iron oxide (FCNP)
based on the protocol reported by Nigam et al. and Bumb
et al.8,10,23 The synthesized FCNP NPs (JCPDS Card
No. 19-0629, a = 8.396 Å) have a negative surface charge
because of the presence of carboxylate group and the aver-
age particle size was ~9 nm (Figure S2).8 From the pre-
pared FCNP (4 mg/mL) solution, 5 mL were stirred with
100 μL of iodomethane at 40C for 12 h and washed with
methanol (12 000 rpm, 10 min). Then, 100 μL of hydra-
zine were added to the mixture and refluxed at 40C for
5 h and stirred overnight at room temperature (RT). The
obtained mixture (HFCNP) was washed with ethanol.
NFHFCNP was prepared by reacting 10 mL of HFCNP
(0.2 mg/mL) with 5 mg of (ρ-SCN-Bn)-NOTA and 8 mg
of folate at RT for 20 h in the presence of triethylamine,
which acts as base. Finally, the resulting mixture
(NFHFCNP) was washed and dispersed in ethanol solu-
tion.8 The structure of synthesized HFCNP and NFHFCP
are shown in Figure 1. The NFHFCNP has folate and
NOTA as a chelate agent on the surface and the HFCNP
has hydrazide with citrate group on the surface. The func-
tional groups on HFCNP have many oxygen and amine
groups as hard Lewis base. In addition, HFCNP can have
dual functions as chelate agent and diagnosis probe. Ga can
be classified as a Lewis acid and form stable coordinated
complexes with oxygen, nitrogen, and sulfur donor
atom.24,25 From the above-mentioned properties, it is clear
that the Ga can easily bind to HFCNP without any chelat-
ing agent as well as NFHFCNP.
Radioisotope 68Ga Labeling with HFCNP and
NFHFCNP. The non-radioactive reference compounds,
GaHFCNP and GaNFHFCNP were prepared by reacting
NPs with GaCl3 stock solution (1:10 molar equiv). The mix-
ture of NPs (0.1 mg/mL, 6 mL) and GaCl3 stock solution
(500 μL) was stirred for 10 min at 100C under refluxing
condition. After 10 min, the mixture was thoroughly washed
and dispersed in deionized water (DW). The radiolabeling
experiment of 68Ga was conducted using 68GaCl3 from
68Ge/68Ga generator (Eckert and Zeigler, Berlin, Germany)
in 0.1 N HCl. Briefly, 1 M sodium acetate buffer (pH 5.5)
was added to 68GaCl3 (1 mCi) followed by the addition of
HFCNP and NFHFCNP (200 μg/mL) under stirring for
10 min at 40C.8,13,14,26 Then, the free 68Ga was eliminated
by centrifugation (5 min, 3000 rpm) and the labeling effi-
ciencies of 68GaHFCNP and 68GaNFHFCNP were measured
using ITLC-SG eluted with 0.1 M citric acid as a mobile
phase.8,26 The AR-2000 radio-TLC Imaging Scanner and
CRC dosemeter were used to measure the radioactivity.
In Vitro Stability of 68Ga Labeling of HFCNP and
NFHFCNP in Human Serum. 68Ga-labeled HFCNP
(200 μL) and NFHFCNP (200 μL) were incubated with
1 mL of human serum at 37C under 5% CO2 for 15, 30,
60, 90, and 120 min to evaluate the in vitro stability. After
each time intervals, the stability was monitored through
ITLC-SG using 0.1 M citric acid.19,20
Release Profile of Doxorubicin-loaded HFCNP and
NFHFCNP. The drug loading efficiency and releasing pro-
file of DOX-(NF)HFCNP was recorded using fluorescence
spectrometer. DOX-loaded (NF)HFCNP was prepared
according to the method proposed by Munnier et al.27 The
drug binding on NPs surface was investigated through a pre-
formed DOX–Fe2+ complex, which is a mixture of DOX
(300 μg/mL in pH 7.4 PBS) and (NH4)2Fe(SO4)26H2O
(450 μg/mL in DW). Then, the DOX–Fe2+ complex was
incubated with (NF)HFCNP under dark for 15 min. Various
mass ratios of DOX 0.20/0.40/0.83/0.96 (w/w) with (NF)
HFCNP (120 μg/mL) were prepared. After incubation, the
DOX-(NF)HFCNP was centrifuged (15 000 rpm, 10 min,
4C) to eliminate the non-conjugated DOX–Fe2+ complex
in supernatant. The DOX-loaded (NF)HFCNP was dis-
persed in sodium buffer solution (pH 4) for 20 min at 37C
in shaking incubator to measure the DOX loading effi-
ciency.27 The sample was centrifuged and the released DOX
concentration in supernatant was measured utilizing fluores-
cence spectrometry (Perkin Elmer LS 55B Luminescence
Spectrometer, Perkin Elmer, Seoul, Korea). The in vitro
release of DOX from (NF)HFCNP was studied in PBS
(pH 7.4) at 37C. To measure the drug releasing rate,
200 μL of DOX-loaded (NF)HFCNP [DOX/(NF)HFCNP—
0.40 (w/w), 120 μg/mL] was added to 3.8 mL of PBS
(pH 7.4) and incubated at 37C under constant shaking.27
After subsequent time intervals, the tube was centrifuged
(15 000 rpm for 10 min, 4C) and the DOX released in
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supernatant from (NF)HFCNP was determined by fluores-
cence spectrometry at 556 nm (excitation wavelength
490 nm, emission range 530–700 nm). Each experiment
was carried out in triplicate.
Cellular Uptake. Cell uptake studies were performed for
KB and A 549 cell lines by the fluorescence microscopy
(EVOS FL Auto, Life Technologies). Initially, the
fluorescein isothiocyanate (FITC)-conjugated (NF)HFCNP
was prepared by mixing (NF)HFCNP solution (120 μg/mL,
1 mL) in ethanol and FITC solution (1 mg/mL, 0.5 mL) in
acetone/water medium (0.3/2.7). As prepared solution was
incubated for 20 h at 37C in shaking incubator under dark
condition.28 Then, the obtained mixture was thoroughly
washed with PBS (pH 7.4) to eliminate the unreacted FITC
and dispersed in 1 mL of cell culture medium (RPMI
1640). Cancer cells were placed in 8-well microscopy
chamber with 1.0 × 104 cells per well and allowed to grow
for 24 h. After incubation, the cells were washed with PBS
and fixed with 4% paraformaldehyde (200 μL) for 15 min,
Then, the cells were again washed and incubated with
FITC-conjugated (NF)HFCNP (200 μL) for 30 min. After
the whole incubation process, the non-uptake (NF)HFCNP
was washed with PBS and the nuclei of cell was stained
with 200 μL of 40,6-diamidino-2-phenylindole (2 μg/mL)
in water for 10 min under dark.29 In addition, to compare
68GaNFHFCNP (with folate) and 68GaNHFCNP (without
folate) uptake by CT-26 (FR+) and SK-BR-3 (FR−) cells,
the cells were placed to grow in a 24-well plate
(1.0 × 105 cells per/well) for 24 h and incubated with
68GaNFHFCNP and 68GaNHFCNP (5 μCi/well) at 40C for
0.5 and 1 h. Then, surface-bound radioactivity materials were
removed using PBS and the cells were suspended in 0.1%
sodium dodecyl sulfate in PBS. The radioactivity of cells and
supernatant was measured by utilizing a gamma counter.8,13,14
Cytotoxicity Evaluation. EZ-CYTOX assay was per-
formed to evaluate in vitro cytotoxicity of DOX-loaded
(NF)HFCNP and Ga(NF)HFCNP on KB and A 549 cell
lines. The 5 × 103 cells/wells were seeded into 96-well flat
bottom plate for 24 h. The 200 μL of various concentration
of DOX-loaded (NF)HFCNP and Ga(NF)HFCNP suspen-
sions (0, 0.391, 0.781, 1.563, 3.125, 6.25, 12.5, 25, 50,
100 μg/mL) were treated to the cells and incubated for
24, 48, and 72 h. The untreated cells were used as a con-
trol. Each experiments were performed in triplicate. After
incubation, EZ-CYOX reagent was added and again incu-
bated for 4 h at 37C. The cell viability was calculated by
recording absorbance at 450 nm.8,10
%Viability = absorbance of sample=absorbance of controlð Þ
×100
Results and Discussion
Figure 2(a) shows the UV–visible absorption spectrum of
nanocomposite with and without folate group. From the
(a) (b)
(c)
Figure 1. Structure of HFCNP without NOTA (a) and NFHFCNP with NOTA-folate (b). The image (c) illustrates the radioisotope (Ga-
68)-labeled nanocomposite-loaded anticancer drug (DOX) for diagnosis (PET/MRI-imaging) and chemotherapy toward cancer.
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resultant figure, the samples FHFCNP and NFHFCNP
show absorption peaks at 280 and 360 nm confirming the
covalent attachment of the folate with NPs.15 But the corre-
sponding folate absorption peaks were not observed in
HFCNP and NHFCNP samples. Thus, the composite
NFHFCNP with folate can easily be attached on tumor cell
for targeted therapeutic.30
After chelating reaction for 10 min, the compound with
radioactivity of 277 μCi of 68GaNFHFCNP and 280 μCi of
68GaHFCNP were separated by centrifugation (3000 rpm,
5 min). The formation of 68GaHFCNP and 68GaNFHFCNP
was shown in Figure 2(b). The chelating peaks of separated
68Ga with NFHFCNP and HFCNP were assigned at
20.5 mm, Rf = 0.103, where the Radiochemical Purity (RP)
was 93.02% for NFHFCNP, 96.74% for HFCNP and the
radioactivities were 254 and 264 μCi, respectively. The
corresponding peaks of free 68Ga with low radioactivities
of 20.2 and 20.4 μCi appeared at 116.4 mm, Rf = 0.582
(RP = 6.98% for NFHFCNP, 3.26% for HFCNP) on 0.1 M
citric acid. These results confirm that the chelating of 68Ga
in (NF)HFCNP can be easily obtained through short reac-
tion time with a high yield. Figure 2(c) shows the expected
structures of 68GaNFHFCNP and 68GaHFCNP, which
depicts that the 68Ga atom was situated in the center of
68GaHFCNP composites, which was further encapsulated
by amine donors and conjugate with citrate group.24,25 The
in vitro stability of 68GaNFHFCNP and 68GaHFCNP com-
posites are shown in Figure S3. The resultant plot displays
that the HFCNP can strongly bind with 68Ga compared
with NFHFCNP, because 68GaHFCNP exhibited higher sta-
bility of ~97.5% than 68GaNFHFCNP of ~87.5% at
120 min. From these results, the encapsulation of Ga in
HFCNP shows more strong binding effect than chelation
effect of NOTA.24,25
Cell uptake of Ga(NF)HFCNP on KB and A 549 cell
lines are shown in Figure S4. The fluorescence microscopic
images show that the FITC-conjugated HFCNP and
NFHFCNP shows high uptake on all cells within very short
incubation time (30 min) compared with long-time incuba-
tion (3, 12, 24, and 48 h) of previous reports.9,29,31 Moreo-
ver, the obtained cell uptake values of 68GaNFHFCNP on
CT-26 (FR+) and SK-BR-3 (FR–) for 0.5 and 1 h incuba-
tion time are shown in Figure 3.
In our previous research, we expected that the SK-BR-3
(FR–) cell membrane have more negatively charged sites
than that of CT-26 (FR+) for high NPs adsorption. But the
68GaNHFCNP composite showed comparatively high
uptake to SK-BR-3 (FR–) than that of CT-26 (FR+) cell
line.8 To enhance the uptake of the NPs on CT-26 (FR+)
(a) (b) (c)
Figure 2. UV–visible absorption spectra for NPs with and without folate (a) and radio thin layer chromatogram (b); expected structure (c);
of 68GaHFCNP (RP: 96.74%) and 68GaNFHFCNP (RP: 93.02%).
Samples Time CT-26 SK-BR-3 
68Ga 
NHFCNP 
30 min 4.199 ± 1.005 8.08 ± 1.049 
60 min 5.997 ± 1.266 11.402 ± 1.092 
68Ga 
NFHFCNP 
30 min 3.005 ± 0.857 3.124 ± 0.588 
60 min 9.764 ± 1.834 10.059 ± 1.014 
Figure 3. Cell uptake of 68GaNFHFCNP on CT-26 (FR+) and
SK-BR-3 (FR–) cell lines at 30 (a) and 60 (b) min.
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cell line, an additional folate functional group was intro-
duced into the 68GaNHFCNP. From Figure 3, it is clear
that the cell uptake values of 68GaNHFCNP and
68GaNFHFCNP were increased with respect to incubation
time. At 30 min incubation, cell uptake of 68GaNHFCNP is
higher than that of 68GaNFHFCNP. But at higher incubation
time (60 min), the cell uptake of 68GaNFHFCNP on CT-26
(FR+) was increased subsequently compared with
68GaNHFCNP because of the presence of additional folate
group. Thus, addition of folate group on the NPs can help
effectively increase the cell uptake of CT-26 (FR+) compare
to NPs without folate. And it showed a similar high uptake
value of SK-BR-3 (FR−) cell line. These results of in vitro
cell uptake of NPs promise for further use in vivo studies.
Drug loading efficiency and releasing profile of DOX
from NPs were estimated using fluorescence spectroscopy.
After the formation of intermediate DOX–Fe2+ complex,
the color of sample changes from bright red (DOX) to dark
red (DOX–Fe2+) as represented in Figure S5. The loading
efficiency of different concentration of DOX on (NF)
HFCNP was calculated using the following relation and the
resultant calibration curve of DOX solution is shown in
Figure S5.27
Loading efficiency %ð Þ = D2=D1× 100
concentration of DOX used before reaction (D1) and after
reaction (D2).
The DOX can bind to NPs by means of ionic interaction
and iron chelation of DOX–Fe2+. The Fe2+ ion has a role to
form an intermediate between DOX and NPs. Both HFCNP
and NFHFCNP have many oxygen and nitrogen groups,
which can easily chelate with iron ion (Figure 1).27 At
pH 6, the DOX is positively charged by protonated primary
amine.10 The surface charge of synthesized HFCNP was
observed to positive charge (+8.84 mV)8 and that of
NFHFCNP shows negative charge (−14.85 mV). Thus, the
DOX has more affinity to bound with negatively charged
NFHFCNP than HFCNP. Figure 4(a) shows the loading
efficiency with respect to various weight ratios of DOX in
HFCNP and NFHFCNP nanocomposites. From the result-
ant plot, the loading efficiency of DOX on HFCNP is
higher than that of NFHFCNP. Moreover, the compounds
exhibit nearly similar value for various mass ratios of
DOX/NPs (0.2/0.4/0.83/0.96). These observations show
that the binding of DOX to HFCNP is mainly afforded by
iron chelation. Moreover, both the compounds possess
almost constant DOX loading efficiency from
31.32  0.19% to 38.28  0.18% for NFHFCNP and
40.74  0.02% to 43.87  0.01% for HFCNP. The result-
ant drug releasing profile of NPs are shown in Figure 4(b).
The release rate of DOX from both the nanocomposite,
HFCNP and NFHFCNP, depend up on time. The DOX
release from NFHFCNP was increased sharply up to 8 h
(47  0.004%) and then, the releasing rate was gradually
slowed and about 67  0.002% released after 48 h.27 The
release of DOX from NFHFCNP could be attributed to the
weakening of the electrostatic interaction between DOX
and NPs.10,27 In case of HFCNP, the DOX was very slowly
released about 19.6  0.32% and 40.9  1.4% after
24 and 48 h by hydrolysis.27 The HFCNP and NFHFCNP
showed a different releasing profiles of drug in spite of the
same base NPs. This experiment evidence that the drug
releasing profile can be adjusted by modifying the surface
state of NPs.
Figure 5(a) shows the cell viability of KB and A549
incubated with Ga(NF)HFCNP for 48 and 72 h. After the
incubation period, KB and A549 cell lines exhibited higher
Figure 4. Loading efficiency of DOX on HFCNP and NFHFCNP (DOX/NPs weight ratio) (a); drug release profile of DOX-loaded NPs
in vitro (PBS pH 7.4) (b).
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viability almost 100% toward Ga(NF)HFCNP. The small
variation of cell viability above 100% may be because of
the properties of iron oxide, which can sometimes facilitate
the cell growth.10 Moreover, the cells can continuously
grow even at high concentration of Ga(NF)HFCNP. This
result represents the nontoxicity and excellent biocompati-
bility of Ga(NF)HFCNP. However, DOX-loaded
NFHFCNP shows high cytotoxicity toward all tested cells,
where each cell was affected by DOX-loaded NFHFCNP
with different force. Even though the low concentration of
DOX can also kills enough cancer cells. The cytotoxicity
of DOX-loaded NFHFCNP for 24 and 48 h was shown in
Figure 5(b). In case of HFCNP, KB and A 549 cell lines
can survived >80% even at strong concentration because of
its slow drug releasing profile. Even after 48 h incubation,
GaHFCNP shows cytotoxicity on the tested cells but the
effects is comparatively less than that of GaNFHFCNP.
These difference in cytotoxicity level is mainly because of
the release rate of NFHFCNP and HFCNP, which was
approximately 67 and 40%, respectively. The exact statisti-
cal values of cell viability and cytotoxicity are shown in
Tables S6 and S7.
Conclusion
In conclusion, we described the synthesis and evaluation of
68Ga-labeled and folate-conjugated Fe3O4 NPs with DOX
as anticancer for dual modality, PET/MRI diagnosis and
targeted cancer therapy. Folate was added to the NPs with
EPR effect and which enhanced the targeting properties of
the NPs. The covalent attachment of folate on NPs were
confirmed through UV–vis absorption spectrum. The
HFCNP and NFHFCNP shows excellent biocompatibility
and high uptake on KB and A 549 cell lines. Cell uptake of
68GaNFHFCNP on CT-26 (FR+) increased with respect to
time comparing with 68GaNHFCNP composite. DOX-
loaded NPs through intermediate DOX–Fe2+ complex have
a high cytotoxicity on the tested cells. The DOX loading
efficiency shows nearly similar value for various mass ratio
of DOX/NPs. The HFCNP showed higher loading effi-
ciency than NFHFCNP and it released about 61  0.001%
and 67  0.002% of loaded DOX after 24 and 48 h,
respectively. But HFCNP shows very slow drug releasing
rate of 19.6  0.32% for 24 h and 40.9  1.4% for 48 h.
These detailed studies establish that 68GaHFCNP and
(a) (b)
Figure 5. Cell viability of GaHFCNP and GaNFHFCNP on KB and A 549 cell lines for 48 and 72 h (a); cytotoxic activity of DOX-
loaded NPs on KB and A 549 cell lines for 24 and 48 h (b).
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68GaNFHFCNP exhibit promising application for cancer
contrast of PET/MRI and developing drug delivery for tar-
geted chemotherapy.
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